🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to co-organize the virtual EACR Boehringer Ingelheim Conference: Drugging & Regulating the MAP Kinase Pathway! Submit an abstract or join us. Please RT and share with others. Details & registration: eacr.org/conference/boe…

Research from Julian Downward Panayiotis Anastasiou and Miriam Molina Arcas at the Crick, working with Revolution Medicines, shows that combining treatments can help to eradicate lung tumours in mice. Read the full story ⤵️ crick.ac.uk/news-and-repor…

Excited to share our last paper out today in Nature Communications Led by the talented Panayiotis Anastasiou #KRAS #immunotherapies #NSCLC

Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade | Nature Communications nature.com/articles/s4146…

"Lung cancer is one of the hardest types of cancer to treat, so working out how to harness the immune system to better target tumours is so important." Read about the new work from Megan Cole, Julian Downward, Febe van Maldegem and more ⤵️ crick.ac.uk/news-and-repor…

Interested on how to combine #KRAS inhibitors with immunotherapies? Check out the last paper of the #Downwardlab and Febe van Maldegem

In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy. science.org/doi/10.1126/sc…

Very excited to share our first #KRAS paper published in Molecular Cancer (rdcu.be/dZZqo [rdcu.be]). We compared KRASG12C and G12D in driving #NSCLC tumorigenesis, seeing that G12D exhibits superior tumorigenicity, dependent on PI3K-AKT-mTOR signaling!

Really grateful for the invitation to speak at this amazing meeting. Hot Topic Meeting: Tolerance and #Resistance to #TargetedTherapy in #NSCLC IASLC #HTTR2024

Happy to report the posting of a new study on compounds that block the interaction of RAS proteins with PI 3-kinase PIK3CA from Vividion Therapeutics @VividionTx, in collaboration with Francis Crick Institute Julian Downward biorxiv.org/content/10.110…

For RAS enthusiasts, register to the 2nd Targeting RAS symposium! Amazing speakers in beautiful Salamanca #RAS #KRAS

It was a pleasure to discuss the progress targeting #KRAS at the #LungCancerNextGen2025

The countdown is on! 🧬🔥 Targeting RAS is coming to Salamanca — join us for cutting-edge science and inspiring discussions on all things RAS! 📍Salamanca (Spain) | 📅 8-10th October Let’s push the boundaries of cancer research together.

1/5 🔬 Meet the Organizing Committee for the Targeting RAS Symposium 2025! A distinguished Organizing Committee of leading researchers and experts is shaping an event dedicated to cutting-edge advances in RAS-driven cancers. #TargetingRAS2025

At yesterday's opening ceremony, we asked the cancer community to stand together to make their voices heard in support of innovative cancer science and medicine. #CancerResearchSavesLives® #AACR25

(1/4) 🔗 Science thrives on connections! 🗨️ At the Targeting RAS Symposium 2025, networking opportunities are an essential part of the experience. The programme has been designed in order to propitiate the exchange of ideas between young talent and established researchers.

We are recruiting! We're searching for a postdoctoral research fellow to study patient-specific regulators of plasticity in primary and metastatic CRC. Please reach out if you have any questions! ucl.ac.uk/work-at-ucl/se…

Join us in Salamanca! The Targeting RAS is back in Salamanca, Oct 8–10, 2025 🎯Great science, great people, great tapas 🗓️ Submit your abstract by July 15! 👉 targetingras.com #TargetingRAS25 #25anniversaryCIC Centro de Investigación del Cáncer/CSIC-USAL-FICUS Miriam Molina Arcas Matthias Drosten AmbrogioLab

Thrilled to share this exciting study ⁦Nature Medicine⁩. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. ⁦MD Anderson Cancer Center⁩ #KRAS #NSCLC

We have spent four great days talking about Small G proteins. Thanks Angeliki Malliri Ian Prior Biochemical Society for the invitation and the organization #BiochemEvent #SGP25